Abstract
Several haemostatic abnormalities are associated with proliferative diabetic retinopathy. While abnormalities in plasma fibrinolytic activity have been described in diabetic retinopathy, platelets (a rich source of plasminogen activator inhibitor type 1, PAI-1) have received little attention. As a result, little is known about the fibrinolytic potential of circulating whole blood in diabetic retinopathy. The concentrations of tissue-type plasminogen activator (t-PA) and of its fast-acting inhibitor. PAI-1 were measured in plasma from eight patients with type 1 diabetes complicated by proliferative retinopathy, and from eight patients with type 1 diabetes and background or no retinopathy, matched for age, sex and duration of diabetes. The concentration of PAI-1 in platelets was also measured. The ratio of t-PTA to PAI-1 in plasma was significantly higher in patients with proliverative retinopathy than in those without (0.66 vs. 0.37, p < 0.02). The average quantitiy of PAI-1 per patelet was significantly lower in the group with proliferative retinopathy (0.33 vs. 0.50 ng/106 platelets, p < 0.02). These data suggest that among patients with type 1 diabetes, total circulating fibrinolytic potential is higher in those with proliferative retinopathy.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 14 October 1998 / Accepted in revised form: 30 September 1999
Rights and permissions
About this article
Cite this article
Simpson, A., Booth, N., Moore, N. et al. Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study. Acta Diabetol 36, 155–158 (1999). https://doi.org/10.1007/s005920050159
Issue Date:
DOI: https://doi.org/10.1007/s005920050159